CASI executive reports 2034 stock option holdings

CASI Pharmaceuticals, Inc. executive Huang Hai, the Global Chief Commercial Officer, reported existing holdings of stock options on Ordinary Shares.

Accepted by SEC EDGAR 04/07/2026 - 04:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

CASI Pharmaceuticals, Inc. executive Huang Hai, the Global Chief Commercial Officer, reported existing holdings of stock options on Ordinary Shares. The filing lists several option awards with exercise prices of $6.61 and $2.67 per share, expiring in 2034. Some options are fully vested and exercisable as of the form date, while certain performance-based options become exercisable only upon achievement of specified performance targets.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Huang Hai

Role Global Chief Commercial Ofcr

Type	Security	Shares	Price	Value
Holding	Option (right to buy)	--	--	--
Holding	Option (right to buy)	--	--	--
Holding	Option (right to buy)	--	--	--
Holding	Option (right to buy)	--	--	--
Holding	Option (right to buy)	--	--	--
Holding	Option (right to buy)	--	--	--
Holding	Option (right to buy)	--	--	--
Holding	Option (right to buy)	--	--	--

Holdings: Option (right to buy) — 280,000 contracts (Direct)

Footnotes (2)

1. F1. The options are fully vested and exercisable as of the date of this form.
2. F2. Performance based options exercisable upon achievement of performance target.

Key Figures

Option exercise price: $6.61 per share Option exercise price: $2.67 per share Underlying shares example: 100,000 shares +4 more

7 metrics

Option exercise price $6.61 per share Exercise price on several options expiring January 29, 2034

Option exercise price $2.67 per share Exercise price on several options expiring June 18, 2034

Underlying shares example 100,000 shares Ordinary Shares underlying one option at $6.61 exercise price

Underlying shares example 75,000 shares Ordinary Shares underlying one option at $6.61 exercise price

Underlying shares example 7,500 shares Ordinary Shares underlying one option at $2.67 exercise price

Expiration date January 29, 2034 Expiry for options with $6.61 exercise price

Expiration date June 18, 2034 Expiry for options with $2.67 exercise price

Key Terms

Option (right to buy), Ordinary Share, fully vested and exercisable, Performance based options

4 terms

Option (right to buy) financial

"security_title: "Option (right to buy)""

Ordinary Share financial

"underlying_security_title: "Ordinary Share""

An ordinary share is a unit of ownership in a company that gives the holder a stake in its profits and usually the right to vote on key decisions. Think of it like a slice of a pizza where each slice entitles you to a portion of what’s left after bills are paid; value can rise or fall with the business and may pay dividends, so it matters to investors for income, growth and control.

fully vested and exercisable financial

"The options are fully vested and exercisable as of the date"

Performance based options financial

"Performance based options exercisable upon achievement of performance target."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does CASI (CASIF) disclose about Huang Hai in this Form 3?

CASI reports that Global Chief Commercial Officer Huang Hai holds multiple stock options on Ordinary Shares. The options include fully vested grants and performance-based awards that become exercisable only if specified performance targets are achieved, all with expiration dates in 2034.

What stock option exercise prices are reported for Huang Hai at CASI (CASIF)?

The Form 3 shows stock options with exercise prices of $6.61 and $2.67 per Ordinary Share. These prices represent the fixed amounts Huang Hai would pay per share if he chooses to exercise the respective option grants in the future.

When do Huang Hai’s CASI (CASIF) stock options expire?

The disclosed stock options held by Huang Hai expire in 2034, with specific expirations on January 29, 2034 and June 18, 2034. After these expiration dates, any unexercised options would lapse and no longer provide the right to purchase Ordinary Shares.

Are Huang Hai’s CASI (CASIF) options already vested and exercisable?

According to a footnote, some options are fully vested and exercisable as of the form date. Another footnote explains that certain performance-based options become exercisable only upon achievement of a performance target, so vesting depends on meeting that condition.

Does this CASI (CASIF) Form 3 show any recent stock purchases or sales by Huang Hai?

The Form 3 primarily lists holdings of stock options rather than recent trades. Transaction summary data shows no categorized buys, sells, exercises, gifts, or tax withholdings, indicating the filing is an initial ownership report, not a record of new market transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Huang Hai

(Last) (First) (Middle)

1701, CHINA CENTRAL OFFICE TOWER 1

NO. 81 JIANGUO ROAD, CHAOYANG DISTRICT

(Street)

BEIJING 100025

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CASI Pharmaceuticals, Inc. [ CASIF ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Global Chief Commercial Ofcr

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	(1)	01/29/2034	Ordinary Share	75,000	$6.61	D
Option (right to buy)	01/29/2027	01/29/2034	Ordinary Share	37,500	$6.61	D
Option (right to buy)	01/29/2028	01/29/2034	Ordinary Share	37,500	$6.61	D
Option (right to buy)	(1)	06/18/2034	Ordinary Share	7,500	$2.67	D
Option (right to buy)	06/18/2026	06/18/2034	Ordinary Share	7,500	$2.67	D
Option (right to buy)	06/18/2027	06/18/2034	Ordinary Share	7,500	$2.67	D
Option (right to buy)	06/18/2028	06/18/2034	Ordinary Share	7,500	$2.67	D
Option (right to buy)	(2)	01/29/2034	Ordinary Share	100,000	$6.61	D

Explanation of Responses:

1. The options are fully vested and exercisable as of the date of this form.

2. Performance based options exercisable upon achievement of performance target.

	/s/ Hai Huang	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)